Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.78 |
| ▸ | CA1 | P00915 | 1/20 | 0.78 |
| ▸ | CA2 | P00918 | 1/20 | 0.78 |
| ▸ | CA3 | P07451 | 1/20 | 0.78 |
| ▸ | CA4 | P22748 | 1/20 | 0.78 |
| ▸ | CA6 | P23280 | 1/20 | 0.78 |
| ▸ | CA5A | P35218 | 1/20 | 0.78 |
| ▸ | CA7 | P43166 | 1/20 | 0.78 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.78 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.78 |
| ▸ | CA9 | Q16790 | 1/20 | 0.78 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.78 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.78 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | CTSS | P25774 | 2/20 | 0.51 |
| ▸ | CTSK | P43235 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | SRC | P12931 | 1/20 | 0.51 |
| ▸ | MME | P08473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL464916 | 1.00 | CA12 (0.78) | CA12CA1CA2CA3CA4 | |
| SCHEMBL1576809 | 0.89 | CA12 (0.78) | CA12CA1CA2CA3CA4 | |
| Lacosamide SCHEMBL35330 | 0.87 | CA12 (1.00) | CA12CA1CA2CA3CA4 | |
| Lacosamide SCHEMBL225889 | 0.87 | CA12 (1.00) | CA12CA1CA2CA3CA4 | |
| Lacosamide SCHEMBL223961 | 0.87 | CA12 (1.00) | CA12CA1CA2CA3CA4 | |
| Lacosamide SCHEMBL28184085 | 0.86 | CA12 (0.97) | CA12CA1CA2CA3CA4 | |
| SCHEMBL2318845 | 0.85 | CA12 (0.80) | CA12CA1CA2CA3CA4 | |
| SCHEMBL8601669 | 0.85 | CA12 (0.94) | CA12CA1CA2CA3CA4 | |
| SCHEMBL2318842 | 0.85 | CA12 (0.80) | CA12CA1CA2CA3CA4 | |
| SCHEMBL993263 | 0.85 | CA12 (0.70) | CA12CA1CA2CA3CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2035029-B1 | PEPTIDE COMPOUNDS FOR TREATING REFRACTORY STATUS EPILEPTICUS | UCB PHARMA GMBH (DE) | 2016-11-30 | — | — | EP | claimed |
| EP-2046386-B1 | PEPTIDE COMPOUNDS FOR THE TREATMENT OF SKELETAL MUSCLE DISORDERS ASSOCIATED WITH ION CHANNEL DYSFUNCTION | UCB PHARMA GMBH (DE) | 2014-07-23 | — | — | EP | claimed |
| US-20140128377-A1 | METHODS OF TREATING REFRACTORY REPETITIVE SEIZURES | UCB PHARMA GMBH (DE) | 2014-05-08 | — | — | US | claimed |
| US-20140066515-A1 | METHODS FOR TREATING CHANNELOPATHIES | UCB PHARMA GMBH (DE) | 2014-03-06 | — | — | US | claimed |
| EP-1915140-B1 | NOVEL USE OF PEPTIDE COMPOUNDS FOR TREATING MUSCLE PAIN | UCB PHARMA GMBH (DE) | 2011-11-23 | — | — | EP | claimed |
| EP-2308482-A1 | Novel use of peptide compounds for treating muscle pain | UCB Pharma GmbH (DE) | 2011-04-13 | — | — | EP | claimed |
| US-20100324144-A1 | THERAPY FOR HYPEREXCITABILITY DISORDERS | SCHWARZ PHARMA AG (DE) | 2010-12-23 | — | — | US | claimed |
| US-20100273714-A1 | PEPTIDE COMPOUNDS FOR TREATING REFRACTORY STATUS EPILEPTICUS | SCHWARZ PHARMA AG (DE) | 2010-10-28 | — | — | US | claimed |
| US-20100260716-A1 | COMPOUNDS FOR TREATING DEMYELINATION CONDITIONS | UCB PHARMA GMBH (DE) | 2010-10-14 | — | — | US | claimed |
| US-20100256179-A1 | COMBINATION THERAPY FOR PAIN IN PAINFUL DIABETIC NEUROPATHY | UCB PHARMA GMBH (DE) | 2010-10-07 | — | — | US | claimed |
| WO-2007144195-A2 | PHARMACEUTICAL COMPOSITION WITH SYNERGISTIC ANTICONVULSANT EFFECT | SCHWARZ PHARMA AG (DE) | 2007-12-21 | — | — | WO | claimed |
| WO-2007141018-A1 | THERAPEUTIC COMBINATION FOR PAINFUL MEDICAL CONDITIONS | SCHWARZ PHARMA AG (DE) | 2007-12-13 | — | — | WO | claimed |
| EP-1841417-A2 | SPM 927 FOR ADD-ON THERAPY OF SCHIZOPHRENIA | SCHWARZ PHARMA AG (DE) | 2007-10-10 | — | — | EP | claimed |
| US-20070197657-A1 | Method for treating non-inflammatory musculoskeletal pain | SRZ PROPERTIES, INC. (US) | 2007-08-23 | — | — | US | claimed |
| US-20070048372-A1 | Method for treating non-inflammatory osteoarthritic pain | SRZ PROPERTIES, INC. (US) | 2007-03-01 | — | — | US | claimed |
| US-20070043120-A1 | Therapeutic combination for painful medical conditions | UCB PHARMA GMBH (DE) | 2007-02-22 | — | — | US | claimed |
| US-20070042969-A1 | Combination therapy for pain in painful diabetic neuropathy | SRZ PROPERTIES, INC. (US) | 2007-02-22 | — | — | US | claimed |
| WO-2007020103-A2 | NOVEL USE OF PEPTIDE COMPOUNDS FOR TREATING MUSCLE PAIN | SCHWARZ PHARMA AG (DE) | 2007-02-22 | — | — | WO | claimed |
| US-20060252749-A1 | Lacosamide for add-on therapy of psychosis | SRZ PROPERTIES, INC. (US) | 2006-11-09 | — | — | US | claimed |
| WO-2006079547-A2 | SPM 927 FOR ADD-ON THERAPY OF SCHIZOPHRENIA | SCHWARZ PHARMA AG (DE) | 2006-08-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256179-A1 | COMBINATION THERAPY FOR PAIN IN PAINFUL DIABETIC NEUROPATHY | GRIN2B, GRIN2A, GRIN3A | CA12 985/4885CA1 535/4885CA2 297/4885 |
| US-20070048372-A1 | Method for treating non-inflammatory osteoarthritic pain | TRPV3, MMP11, MMP13 | CA12 114/4885CA1 102/4885CA2 8/4885 |
| US-20070042969-A1 | Combination therapy for pain in painful diabetic neuropathy | GRIN2B, GRIN2A, GRIN3A | CA12 985/4885CA1 535/4885CA2 297/4885 |
| US-20140066515-A1 | METHODS FOR TREATING CHANNELOPATHIES | HCN3, KCNN3, KCNN2 | CA12 3479/4885CA1 1323/4885CA2 407/4885 |
| US-20100273714-A1 | PEPTIDE COMPOUNDS FOR TREATING REFRACTORY STATUS EPILEPTICUS | VIP, VGF, PRSS12 | CA12 798/4885CA1 92/4885CA2 679/4885 |
| US-20070197657-A1 | Method for treating non-inflammatory musculoskeletal pain | TNNC1, MMP11, MMP14 | CA12 379/4885CA1 734/4885CA2 59/4885 |
| US-20140128377-A1 | METHODS OF TREATING REFRACTORY REPETITIVE SEIZURES | GABRE, GRIK2, GABRR1 | CA12 624/4885CA1 60/4885CA2 312/4885 |
| US-20070043120-A1 | Therapeutic combination for painful medical conditions | PDE1B, CA2, CACNA1S | CA12 93/4885CA1 105/4885CA2 2/4885 |
| US-20100324144-A1 | THERAPY FOR HYPEREXCITABILITY DISORDERS | SCN1A, SLC1A2, SLC1A3 | CA12 3611/4885CA1 1206/4885CA2 880/4885 |
| US-20060252749-A1 | Lacosamide for add-on therapy of psychosis | SLC6A11, SLC6A3, SLC6A1 | CA12 1355/4885CA1 689/4885CA2 553/4885 |
| US-20100260716-A1 | COMPOUNDS FOR TREATING DEMYELINATION CONDITIONS | PMP22, MAG, MYT1 | CA12 362/4885CA1 98/4885CA2 677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.